CD352, also known as SLAMF6, is a homotypic binding receptor expressed on both resting and activated PBMC, and its absence significantly ameliorated CD8+T cells mediated tumor regression, suggesting that it serves as an inhibitory checkpoint. This evidence concerns the gene SLAMF6 and neoplasm.